Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Garsorasib is an inhibitor of K-Ras containing the activating glycine-to-cysteine mutation at position 12 (K-RasG12C; IC50 = 18 nM).1 It selectively binds to GDP-bound K-RasG12C over GDP-bound wild-type K-Ras in thermal shift assays and selectively inhibits ERK phosphorylation in NCI H358 cells, which express K-RasG12C, over NCI H1993 cells, which express wild-type K-Ras (IC50s = 6.9 and >1,000 nM, respectively). Garsorasib inhibits proliferation in 11 K-RasG12C-expressing cancer cell lines (IC50s = 4.6-33 nM) but not in K-RasG12D- or wild-type-expressing cancer cells (IC50s = >10,000 nM). In vivo, garsorasib (30 mg/kg) induces tumor regression in NCI H358 non-small cell lung cancer (NSCLC) and MIA PaCa-2 pancreatic cancer mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. D-